以岭药业专利中药全球注册情况 "走出去"：理论先行，科技破局，让中医药惠及世界 11月22日，来自越南、泰国、中国、加拿大等国家和地区的专家学者齐聚一堂，围绕络病理论的最新科 研进展展开深入交流，共商中医药现代化与国际化发展路径。 第二十一届国际络病学大会海外论坛在越南举行 "走出去"是中医药国际化的关键起点。以岭药业深知，中医药要走向世界，理论必须先行。33年来，企 业以"科技创新，成果转化，产业发展"为核心发展战略，系统构建了络病理论体系。该体系被国医大师 路志正评价为"中医络病学发展史上的第四个里程碑"。 以岭医药研究院中医药分院副院长、络病研究部主任李红蓉博士在采访时介绍称，以岭药业从"络病证 治"到"脉络学说"再到"气络学说"，搭建完成了络病研究三大理论框架，相关专著如《络病学》《脉络 论》《气络论》已出版发行，为中医络病学学科发展奠定了坚实的理论基础，《络病学》英文版教材在 弗吉尼亚整合医学大学、加拿大安大略中医学院、新加坡中医学院等海外教育机构开课，助力国际中医 药人才培养。以岭药业在该理论指导下继承创新，创立了"理论+临床+新药+实验+循证"一体化的中医 学术创新与转化新模式。 基于坚实的络病 ...

越南南医协会主席张越平致辞时指出，络病理论是非常重要的一个理论，国际络病学大会作为该领域的 重要学术平台，多年来始终引领着络病学研究的前沿方向，推动着理论创新与临床实践的深度融合。 "我们欣喜地看到络病理论在现代科学的验证下不断焕发新的生机，其系统性的思维方式，在防治心脑 血管疾病、糖尿病等疾病方面展现出的独特疗效，这为包括越南传统医学在内的各国传统医学的现代化 发展提供了成功的范例。"张越平表示，希望未来能与中国及各国的研究机构建立更加亲密的合作伙伴 关系，共同开展络病学术研究与信息共享。 越南传统医药大学副校长段光辉致辞时表示，络病学说日益完善，创新成果不断发展，为全球传统医学 的现代化贡献了巨大的科学潜力。作为越南一所国家重点院校，越南传统医药大学始终致力于将络病学 研究成果融入教学，培养与科研体系中鼓励教师与学生深入学习研究络病学，为推动传统医学创新发展 贡献力量。 中医络病理论体系可追溯至春秋战国时期，《黄帝内经》首次提出"经脉""经络""血脉""络脉""络病"概 念及络病治疗。东汉张仲景在《伤寒杂病论》首次提出"脉络"，创立通络治疗方药。清代叶天士进一步 提出"久病入络""久痛入络"，发展络病治疗 ...

11月22日，第二十一届国际络病学大会海外论坛在越南河内召开。本次论坛由世界中医药学会联合会络病专业委员会与越南南医协会联合主办，以"合作、 传承、创新、融合"为理念，会聚了来自海内外多个国家的行政管理者、行业领军专家、学者及科研人员，围绕络病理论指导心脑血管、内分泌、呼吸、抗 衰老、肿瘤等领域疾病防治的学术进展和重大科研成果展开深入交流。 中国驻越南大使馆公参邬国权指出，健康是人类共同的追求，传统医药是世界共享的宝贵财富。络病理论作为中医药创新转化的典范，在心血管疾病与慢病 防治等领域的价值已获国际高度认可。中方一贯重视传统医药的传承、创新与国际合作，此次论坛不仅是络病学交流的重要平台，也是中越合作的重要契 机。中国驻越南使馆将继续发挥桥梁作用，支持两国科研机构、高校、医院与企业开展多元合作，共同推动传统医药现代化与国际化，为构建人类卫生健康 共同体作出贡献。 越南传统医药大学副校长段光辉表示，络病理论体系日益完善，创新成果不断涌现，尤其在心血管、呼吸、内分泌等慢性疾病的防治方面取得重要突破，展 现出传统医学在现代科学背景下的巨大潜力。该校致力于将络病学研究成果融入教学、科研与人才培养体系，鼓励师生深入参与 ...

以岭药业总部 "络病理论是中医药学独特的组成部分，也是以岭药业研发体系的核心灵魂。"吴瑞告诉记者，在络病理论指导下，以岭药 业建立起"理论—临床—科研—产业—教学"五位一体运营模式，形成了"理论+临床+新药+实验+循证"一体化的中医药创新 转化路径。 截至目前，以岭药业成功研发17个专利中药，覆盖心脑血管、呼吸、糖尿病、肿瘤、神经、泌尿、妇科、抗衰老等八大疾 病领域，其中11个品种进入国家医保目录、5个进入国家基药目录，成为中医药创新转化的典范。 "研发不是成本，而是我们最核心的增长动力。"吴瑞告诉记者，以岭的每一根增长曲线，都源自研发的持续投入与突破。 今年前三季度，公司实现归母净利润10亿元，同比增长80.33%。其中，第三季度，公司实现归母净利润3.32亿元，单季盈 利创历史新高。公司前三季度研发费用支出达5.44亿元，占营收比例9.27%，持续位居中药行业前列。 ◎记者 刘立 闫刘梦 从一本《络病学》教材到在海内外建立130余家络病专业委员会，从一味院内制剂到17款专利新药，从一家河北药企到国 际化医药集团……这就是国内中医药产业领军企业以岭药业的成长轨迹。 "以岭将科技创新作为立企之本，以络病理论为 ...

Group 1 - The core viewpoint of the article highlights the strategic developments and growth trajectories of various companies in Hebei, including their market performance and innovative initiatives [11][19][20]. - Hebei's listed companies have implemented market value management plans, with 74 companies executing annual and mid-term dividends totaling over 28 billion yuan [11]. - Yiling Pharmaceutical has increased its market share in the cardiovascular oral traditional Chinese medicine market from 13.64% in 2015 to 18.13% in 2024, serving as a stable growth driver for the company [11][28]. Group 2 - Wireless Media is expanding its business from traditional IPTV services to smart home and enterprise digitalization, aiming to redefine the value of large screens through technology [12][13]. - The company has a user base of nearly 15 million IPTV subscribers, and it is actively developing a smart media cloud platform to create a new ecosystem combining AI and new media [13][15]. - Financial support for local enterprises has been significant, with Financial Securities issuing 8 rounds of science and technology bonds totaling 8.2 billion yuan to support R&D investments [20][23]. Group 3 - Colin Electric aims to become a world-class comprehensive energy service provider by integrating smart grids, renewable energy, and comprehensive energy services [32][34]. - The company has seen significant growth in its renewable energy sector, focusing on photovoltaic and energy storage solutions, and is transitioning from equipment supplier to integrated solution provider [33][36]. - In the third quarter, Colin Electric reported a revenue of 3.216 billion yuan, a year-on-year increase of 23.63%, and a net profit of 217 million yuan, marking a 45.9% increase [36]. Group 4 - Yiling Pharmaceutical has established a comprehensive R&D system guided by the theory of "Luo Disease," leading to the successful development of 17 patented traditional Chinese medicines [26][28]. - The company emphasizes the importance of R&D as a core growth driver, with R&D expenses accounting for 9.27% of revenue, positioning it among the leaders in the traditional Chinese medicine industry [28][29]. - Yiling's products have gained international recognition, with significant studies published in top medical journals demonstrating their efficacy in treating cardiovascular conditions [29][30].

Core Viewpoint - Yiling Pharmaceutical reported strong financial performance in the first half of 2025, with significant growth in revenue and net profit, driven by effective cost control and cash flow management [1] Financial Performance - The company achieved operating revenue of 4.04 billion yuan and a net profit attributable to shareholders of 669 million yuan, representing year-on-year growth of 26.03% [1] - The non-recurring net profit was 641 million yuan, with a year-on-year increase of 27.08% [1] - Operating costs decreased by 23.76%, and selling expenses fell by 15.28% [1] - Net cash flow from operating activities surged by 214.97% to 832 million yuan, with cash and cash equivalents at 1.003 billion yuan and a debt-to-asset ratio of 21.81% [1] Business Segments - The proprietary Chinese medicine segment remains the main revenue source, contributing 1.963 billion yuan from cardiovascular products, accounting for 48.6% of total revenue with a gross margin of 65.54% [3] - The company has 17 proprietary Chinese medicines, with 11 included in the 2024 National Medical Insurance Directory and 5 in the National Essential Drug List, covering eight major systems [3] - The chemical medicine segment is accelerating international expansion, with 4 innovative drug candidates in clinical stages and 15 ANDA products approved by the FDA [3][4] Research and Development - The company invests heavily in R&D, with an expenditure of 399 million yuan, representing 9.87% of revenue, and holds 870 valid patents, including 511 invention patents [6] - The establishment of a multi-level academic society system supports the research and promotion of the company's products, enhancing their market value [6]

Core Viewpoint - Yiling Pharmaceutical has demonstrated strong resilience with a return to double-digit profit growth in the first half of 2025, achieving a net profit of 669 million yuan, a year-on-year increase of 26.03% [1] Product Dimension - Yiling Pharmaceutical has established a diversified pharmaceutical health industry structure, driven by three main sectors: patented traditional Chinese medicine, chemical drugs, and health industry [2] - The patented traditional Chinese medicine segment remains the profit cornerstone, contributing 1.963 billion yuan in revenue, accounting for 48.6% of total revenue, with a gross margin of 65.54% [2] - The chemical drug business is crucial for international market expansion, with significant progress in the development of innovative drugs and a well-structured product pipeline [2] - The health industry aligns with the "Healthy China 2030" strategy, focusing on modern health needs and creating a unique health product system [3] Theoretical Dimension - The theory of "Luo Disease" serves as a foundational pillar for Yiling Pharmaceutical's product development and is a core competitive advantage [4] - The company has developed numerous innovative traditional Chinese medicines under this theoretical framework, enhancing its academic standing and market competitiveness [4] R&D Dimension - Yiling Pharmaceutical invested 399 million yuan in R&D in the first half of 2025, representing 9.87% of its revenue, positioning it at a leading level within the industry [6] - The company has established various innovation platforms and a comprehensive drug integration innovation technology system to support future R&D efforts [6][7] - The company holds 870 valid patents, including 511 invention patents, which will bolster its future product offerings and market competitiveness [8]

Core Viewpoint - The newly released guideline recommends the innovative traditional Chinese medicine, Shen Song Yang Xin Capsule, for the management of atrial fibrillation (AF), marking a significant milestone in integrating traditional Chinese medicine into modern cardiovascular treatment [1][2][14]. Group 1: Guideline Development and Significance - The guideline was developed by 67 experts from various medical associations, incorporating recent research and consensus on atrial fibrillation management [1]. - It emphasizes a comprehensive management approach for AF, integrating prevention, acute treatment, and long-term follow-up, highlighting the importance of multidisciplinary collaboration [2][3]. Group 2: Clinical Evidence and Recommendations - Shen Song Yang Xin Capsule is recommended for maintaining sinus rhythm in paroxysmal AF patients and reducing recurrence rates in patients post-radiofrequency ablation [1][4]. - The capsule's efficacy was supported by a multi-center randomized controlled trial involving 349 patients, showing a total effective rate of 62.3%, comparable to the drug Propafenone [5][7]. Group 3: Mechanism and Unique Advantages - The capsule operates through a unique formulation that addresses both rapid and slow heart rhythms, making it particularly suitable for elderly patients who may experience both types of arrhythmias [9][12]. - Its mechanism includes regulating ion channels and autonomic nervous functions, which helps improve cardiac conduction and stabilize heart rates [10][11]. Group 4: Future Implications and Research Directions - The inclusion of Shen Song Yang Xin Capsule in the guideline is expected to enhance the treatment options available for AF, particularly in the context of post-ablation management [14][15]. - Experts advocate for further high-quality clinical research to validate the efficacy of traditional Chinese medicine in treating arrhythmias, aiming for broader acceptance and integration into global treatment protocols [15][16].

Core Viewpoint - Yiling Pharmaceutical has received approval from the Macao Health Bureau for its innovative traditional Chinese medicine, Qifang Bitong Pian, marking a significant milestone in the development of traditional Chinese medicine in Macao [1][3]. Company Summary - Yiling Pharmaceutical's subsidiary, Yiling (Macao) Co., Ltd., has been granted the first registration certificate for an innovative traditional Chinese medicine by the Macao Health Bureau [1]. - Qifang Bitong Pian is designed to treat persistent allergic rhinitis, addressing symptoms such as sneezing, runny nose, nasal congestion, and fatigue [3]. - The company holds complete intellectual property rights for Qifang Bitong Pian, which is based on the theory of "lung and spleen deficiency" in allergic rhinitis treatment [3]. Industry Summary - The approval of Qifang Bitong Pian represents a new treatment option for patients with allergic rhinitis and revitalizes the application of traditional Chinese medicine in the field of otolaryngology [3]. - Yiling Pharmaceutical is leveraging modern high-tech innovations to drive the industrialization of traditional Chinese medicine, with 17 patented new drugs, including 11 listed in the national medical insurance directory [4]. - The company is advancing its research pipeline with two traditional Chinese medicines already submitted for production and six in clinical stages, alongside numerous hospital preparations as a reserve for new drug development [4].

Core Viewpoint - The announcement by the National Medical Products Administration regarding the optimization of clinical trial review and approval for innovative drugs is a significant positive development for the industry, particularly as it reduces the review time from 60 to 30 working days for innovative drug applications, including traditional Chinese medicine (TCM) [1] Group 1: Industry Overview - The recognition of TCM as an essential part of innovative drugs contrasts with the capital market's perception, which has not seen significant growth in TCM companies despite a surge in innovative drug stocks this year [1] - The modernization of TCM is gaining traction, supported by national policies, emphasizing the integration of traditional advantages with modern scientific techniques [3][4] Group 2: Company Profile - Yiling Pharmaceutical - Yiling Pharmaceutical is a leading innovative drug company with a focus on TCM, biopharmaceuticals, and health products, with TCM being the primary revenue and profit contributor [1] - As of the end of 2024, Yiling Pharmaceutical holds 17 patented TCM products covering eight major clinical disease systems, leading in the cardiovascular and respiratory disease treatment sectors [1] Group 3: Financial Performance - In 2024, Yiling Pharmaceutical's revenue from cardiovascular drugs exceeded 3.8 billion, while respiratory drugs accounted for less than 800 million, together representing over 70% of total revenue [9] - The company has experienced a decline in revenue over the past two years, primarily due to a significant drop in demand for its product Lianhua Qingwen post-pandemic [11] Group 4: Research and Development - Yiling Pharmaceutical has consistently ranked among the top in R&D investment within the A-share TCM sector, with annual R&D expenditures of approximately 895 million, 935 million, and 908 million over the past three years, representing 7.15%, 9.06%, and 13.94% of revenue respectively [5] - The company has achieved notable academic breakthroughs, including a landmark study published in a top medical journal demonstrating the efficacy of its product Tongxinluo in reducing cardiovascular events [6] Group 5: Growth Potential - Yiling Pharmaceutical's core competitive advantage lies in its founder's innovative theory on vascular diseases, which has attracted international research interest [12] - The company has five new drugs approved in the past five years, with four included in the medical insurance directory, indicating a strong pipeline for future growth [12] - The current market valuation of Yiling Pharmaceutical is estimated to be around 300 billion, with potential for significant appreciation as the market begins to recognize the value of innovative TCM [16]